Arcutis Biotherapeutics (ARQT) EBIT Margin (2022 - 2026)
Arcutis Biotherapeutics (ARQT) posted quarterly EBIT Margin of 8.62% for Q1 2026, up 2980.0% year-over-year from 0.28% in Q1 2025, and down 160.74% quarter-over-quarter from 14.2% in Q4 2025.
Arcutis Biotherapeutics (ARQT) EBIT Margin (2022 - 2026) Analysis & Trends
Arcutis Biotherapeutics' EBIT Margin history runs 5 years deep, the most recent figure standing at 8.62% for Q1 2026.
- In Q1 2026, EBIT Margin rose 2980.0% year-over-year to 8.62%; the TTM figure through Mar 2026 stood at 0.77% (up 5886.0% YoY), while the FY2025 annual figure was 3.25%, up 7384.0% from the prior year.
- EBIT Margin for Q1 2026 stood at 8.62%, down from 14.2% in the prior quarter.
- The five-year high for EBIT Margin was 14.2% in Q4 2025, with the low at 14448.0% in Q3 2022.
- The 5-year median for EBIT Margin is 96.84% (2023), against an average of 1439.08%.
- The sharpest annual moves came in 2023 and 2024: EBIT Margin soared 1435116 bps in 2023, then surged 955 bps in 2024.
- Arcutis Biotherapeutics' EBIT Margin stood at 2310.84% in 2022, then surged by 94 bps to 139.19% in 2023, then jumped by 92 bps to 11.0% in 2024, then soared by 229 bps to 14.2% in 2025, then slumped by 161 bps to 8.62% in 2026.
- Business Quant data shows ARQT's EBIT Margin at 8.62% in Q1 2026, 14.2% in Q4 2025, and 8.59% in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | EBIT Margin (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn | 37.40% |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn | 30.15% |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn | 31.68% |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - | - |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn | 19.06% |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn | -105.20% |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - | 19.75% |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn | 17.93% |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn | -0.36% |
| 10 | Arcutis Biotherapeutics | 3.29 Bn | 3.05 Bn | 118.92 Mn | 12.65% |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 12.65% |
| Mar 31, 2026 | -8.62% |
| Dec 31, 2025 | 14.20% |
| Sep 30, 2025 | 8.59% |
| Jun 30, 2025 | -17.93% |
| Mar 31, 2025 | -38.42% |
| Dec 31, 2024 | -11.00% |
| Sep 30, 2024 | -87.29% |
| Jun 30, 2024 | -162.28% |
| Mar 31, 2024 | -146.61% |
| Dec 31, 2023 | -139.19% |
| Sep 30, 2023 | -96.84% |
| Jun 30, 2023 | -1,399.64% |
| Mar 31, 2023 | -2,742.36% |
| Dec 31, 2022 | -2,310.84% |
| Sep 30, 2022 | -14,448.00% |